financetom
Business
financetom
/
Business
/
Masimo smartwatches infringe Apple design patents, US jury says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Masimo smartwatches infringe Apple design patents, US jury says
Nov 3, 2024 12:04 PM

Oct 25 (Reuters) - Apple ( AAPL ) convinced a federal

jury on Friday that health monitoring tech company Masimo's ( MASI )

smartwatches infringe two of its design patents.

The jury, in Delaware, agreed with Apple ( AAPL ) that Masimo's ( MASI ) W1

and Freedom watches and chargers willfully violated Apple's ( AAPL )

patent rights in smartwatch designs, awarding the tech giant

$250 in damages. Apple's ( AAPL ) attorneys told the court the "ultimate

purpose" of its lawsuit was to win an injunction against sales

of Masimo's ( MASI ) smartwatches after an infringement ruling.

The jury also determined that Masimo's ( MASI ) watches did not

infringe Apple ( AAPL ) patents covering smartwatch inventions that the

tech giant had accused Masimo ( MASI ) of copying.

Masimo ( MASI ) said in a statement that the company appreciated the

jury's verdict "in favor of Masimo ( MASI ) and against Apple ( AAPL ) on nearly

all issues," and that the decision only applied to a

"discontinued module and charger."

"Apple ( AAPL ) primarily sought an injunction against Masimo's ( MASI )

current products, and the jury's verdict is a victory for Masimo ( MASI )

on that issue," Masimo ( MASI ) said.

Apple ( AAPL ) said in a statement that it was "glad the jury's

decision today will protect the innovations we advance on behalf

of our customers."

Irvine, California-based Masimo ( MASI ) accused Apple ( AAPL ) of hiring

away its employees and stealing its pulse oximetry technology

after discussing a potential collaboration. Masimo ( MASI ) convinced the

U.S. International Trade Commission last year to block imports

of Apple's ( AAPL ) Series 9 and Ultra 2 smartwatches after the

commission found that their technology for reading blood oxygen

levels infringed Masimo's ( MASI ) patents.

Apple ( AAPL ) has appealed the decision and resumed selling the

watches after removing the technology. The tech giant

countersued Masimo ( MASI ) for patent infringement in 2022, alleging

that Masimo ( MASI ) copied Apple Watch features to use in its

smartwatches.

Apple ( AAPL ) also accused Masimo ( MASI ) of using lawsuits at the ITC

and in California to "make way for Masimo's ( MASI ) own watch." Masimo ( MASI )

said Apple's ( AAPL ) patent lawsuit was "retaliatory" and "an attempt to

avoid the court in which the parties have been litigating their

dispute."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Wingstop Stock Slides As Same-Store Sales Guidance Falters
Wingstop Stock Slides As Same-Store Sales Guidance Falters
Apr 29, 2026
Wingstop Inc ( WING ) shares are trading lower Wednesday morning following mixed fiscal first-quarter results and a cautious 2026 outlook. Here’s what investors need to know. Wingstop ( WING ) stock is among today’s weakest performers. What’s weighing on WING shares? Mixed Q1 Results Pressure WING Shares For the period ended March 28, 2026, Wingstop ( WING ) reported...
Sector Update: Consumer Stocks Lean Lower Premarket Wednesday
Sector Update: Consumer Stocks Lean Lower Premarket Wednesday
Apr 29, 2026
09:09 AM EDT, 04/29/2026 (MT Newswires) -- Consumer stocks were leaning lower premarket Wednesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) down 0.2% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) declining by 0.4%. Bunge Global ( BG ) shares were up more than 2% after the company posted higher Q1 adjusted earnings...
AstraZeneca to invest $405 million in Britain after US-UK pharma deal
AstraZeneca to invest $405 million in Britain after US-UK pharma deal
Apr 29, 2026
* Investment follows US-UK deal aimed at increased drug prices * Starmer says investment will future-proof 1,000 jobs * AstraZeneca ( AZN ) had pulled back on UK investments last year (Adds quote from AstraZeneca ( AZN ) CEO in paragraphs 5 and 7) LONDON, April 29 (Reuters) - Prime Minister Keir Starmer said on Wednesday that Britain's biggest company...
CTS Q1 Adjusted Earnings, Net Sales Rise; Narrows 2026 Guidance
CTS Q1 Adjusted Earnings, Net Sales Rise; Narrows 2026 Guidance
Apr 29, 2026
09:09 AM EDT, 04/29/2026 (MT Newswires) -- CTS (CTS) reported Q1 adjusted earnings Wednesday of $0.62 per diluted share, up from $0.44 a year earlier. An analyst polled by FactSet expected $0.52. Net sales for the quarter ended March 31 were $139.2 million, up from $125.8 million a year earlier. An analyst surveyed by FactSet expected $136.8 million. The company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved